Literature DB >> 17288451

RNA-p53 interactions in vitro.

Kasandra J-L Riley1, Marina Ramirez-Alvarado, L James Maher.   

Abstract

The tumor suppressor protein p53 is mutated in over half of human cancers. Despite 25 years of study, the complex regulation of this protein remains unclear. After serendipitously detecting RNA binding by p53 in the yeast three-hybrid system (Y3H), we are exploring the specificity and function of this interaction. Electrophoretic mobility shift assays show that full-length p53 binds equally to RNAs that are strongly distinguished in the Y3H. RNA binding blocks sequence-specific DNA binding by p53. The C-terminus of p53 is necessary and sufficient for strong RNA interaction in vitro. Mouse and human C-terminal p53 peptides have different affinities for RNA, and an acetylated human p53 C-terminal peptide does not bind RNA. Circular dichroism spectroscopy of p53 peptides shows that RNA binding does not induce a structural change in the p53 C-terminal peptide, and C-terminal peptides do not detectably affect the structure of RNA. These results demonstrate that p53 binds RNA with little sequence specificity, RNA binding has the potential to regulate DNA binding, and RNA-p53 interactions can be regulated by acetylation of the p53 C-terminus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17288451     DOI: 10.1021/bi061480v

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  The history of p53. A perfect example of the drawbacks of scientific paradigms.

Authors:  Thierry Soussi
Journal:  EMBO Rep       Date:  2010-10-08       Impact factor: 8.807

Review 2.  p53 RNA interactions: new clues in an old mystery.

Authors:  Kasandra J-L Riley; L James Maher
Journal:  RNA       Date:  2007-09-05       Impact factor: 4.942

3.  Analysis of p53-RNA interactions in cultured human cells.

Authors:  Kasandra J-L Riley; L James Maher
Journal:  Biochem Biophys Res Commun       Date:  2007-09-10       Impact factor: 3.575

4.  Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain.

Authors:  Petar Stefanov Kovachev; Debapriya Banerjee; Luciana Pereira Rangel; Jonny Eriksson; Murilo M Pedrote; Mafalda Maria D C Martins-Dinis; Katarina Edwards; Yraima Cordeiro; Jerson L Silva; Suparna Sanyal
Journal:  J Biol Chem       Date:  2017-04-18       Impact factor: 5.157

5.  SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53.

Authors:  Cian J Lynch; Zahid H Shah; Simon J Allison; Shafiq U Ahmed; Jack Ford; Lorna J Warnock; Han Li; Manuel Serrano; Jo Milner
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

Review 6.  Anti-Transcription Factor RNA Aptamers as Potential Therapeutics.

Authors:  Estefanía Mondragón; Louis James Maher
Journal:  Nucleic Acid Ther       Date:  2015-10-28       Impact factor: 5.486

7.  Novel RNA-binding activity of MYF5 enhances Ccnd1/Cyclin D1 mRNA translation during myogenesis.

Authors:  Amaresh C Panda; Kotb Abdelmohsen; Jennifer L Martindale; Clara Di Germanio; Xiaoling Yang; Ioannis Grammatikakis; Ji Heon Noh; Yongqing Zhang; Elin Lehrmann; Dawood B Dudekula; Supriyo De; Kevin G Becker; Elizabeth J White; Gerald M Wilson; Rafael de Cabo; Myriam Gorospe
Journal:  Nucleic Acids Res       Date:  2016-01-26       Impact factor: 16.971

8.  Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.

Authors:  Jiacheng Lou; Yuchao Hao; Kefeng Lin; Yizhu Lyu; Meiwei Chen; Han Wang; Deyu Zou; Xuewen Jiang; Renchun Wang; Di Jin; Eric W-F Lam; Shujuan Shao; Quentin Liu; Jinsong Yan; Xiang Wang; Puxiang Chen; Bo Zhang; Bilian Jin
Journal:  Mol Cancer       Date:  2020-09-07       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.